Prodromal non-motor symptoms of Parkinson's disease

Neuropsychiatric Disease and Treatment

Volumn 3, Issue 1, 2007, Pages 145-151

  Pellicano, Clelia ^a   Benincasa, Dario ^a   Pisani, Vincenzo ^a   Buttarelli, Francesca R ^a   Giovannelli, Morena ^a   Pontieri, Francesco E ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Autonomic dysfunction; Depression; Non motor symptoms; Olfactory dysfunction; Parkinson's disease; RBD

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 8 HYDROXYDEOXYGUANOSINE; ANTIPARKINSON AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; COPPER ZINC SUPEROXIDE DISMUTASE; DOPAMINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; GLUTAMATE RECEPTOR ANTAGONIST; GLUTATHIONE REDUCTASE; LEVODOPA; MALONALDEHYDE; NEUROPROTECTIVE AGENT; PHENYLEPHRINE; PILOCARPINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SUPEROXIDE; TYROSINE 3 MONOOXYGENASE; UBIDECARENONE;

ANXIETY; BLOOD ANALYSIS; BRADYKINESIA; CELL TYPE; CORRELATION ANALYSIS; DAYTIME SOMNOLENCE; DEGENERATIVE DISEASE; DEPRESSION; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DRUG RESEARCH; DYSAUTONOMIA; EARLY DIAGNOSIS; ECHOGRAPHY; HUMAN; LEWY BODY; MEDICAL LITERATURE; MEDULLA OBLONGATA; MESENCEPHALON; MUSCLE RIGIDITY; NEOCORTEX; NERVE DEGENERATION; NEUROPATHOLOGY; OXIDATIVE STRESS; PARASOMNIA; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; QUALITY OF LIFE; RELIABILITY; REVIEW; RISK ASSESSMENT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SLEEP DISORDER; SMELLING DISORDER; SUBSTANTIA NIGRA; SYMPTOM; TREMOR;

EID: 34249020435     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/nedt.2007.3.1.145     Document Type: Review

References (78)

1. Abbott RD, Petrovitch H, White LR, et al. 2001. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology, 57:456-62.
2. Abbott RD, Ross GW, White LR, et al. 2005. Excessive daytime sleepiness and subsequent development of Parkinson's disease. Neurology, 65:1442-6.
3. Abe T, Isobe C, Murata T, et al. 2003. Alteration of 8-hydroxyguanosine concentrations in the cerebrospinal fluid and serum from patients with Parkinson's disease. Neurosci Lett, 336:105-8.
4. Ansari KA, Johnson A. 1975. Olfactory dysfunction in patients with Parkinson's disease. J Chronic Dis, 28:493-7.
5. Bannister R, Mathias CJ. 1999. Clinical features and evaluation of primary chronic autonomic failure syndromes. In: Mathias CJ, Bannister R (eds). Autonomic failure. 4th ed. Oxford: Oxford Univ. Pr. pp. 307-16.
6. Barbanti P, Fabbrini G, Ricci A, et al. 1999. Increased expression of dopamine receptors on lymphocytes in Parkinson's disease. Mov Disord, 14:764-77.
7. Becker G, Seufert J, Bogdahn U, et al. 1995. Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography. Neurology, 45:182-4.
8. Behnke S, Berg D, Naumann M, et al. 2005. Differentiation of Parkinson's disease and atypical parkinsonian syndromes by transcranial ultrasound. J Neurol Neurosurg Psychiatry, 76:423-5.
9. Benarroch EE. 1999. Central neurotransmitters and neuromodulators in cardiovascular regulation. In: Mathias CJ, Bannister R (eds). Autonomic failure. 4th ed.Oxford: Oxford Univ. Pr. pp. 37-44.
10. Berg D, Becker G, Zeiler B, et al. 1999. Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology, 53:1026-31.
11. Berg D, Siefker C, Becker G. 2001. Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. J Neurol, 8:684-9.
12. Berg D, Roggendorf W. Schroder U, et al. 2002. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol, 59:999-1005.
13. Bonifati V, Oostra BA, Heutink P. 2004. Unraveling the pathogenesis of Parkinson's disease - the contribution of monogenic forms. Cell Mol Lift Sci, 61:1729-50.
14. Braak H, Del Tredici K, Rub U, et al. 2003. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging, 24:197-211.
15. Braak H, Ghebremedhin E, Rub U, et al. 2004. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res, 318:121-34.
16. Burgut FT, Benaur M, Hencliffe C. 2006. Late-life depression:a neuropsychiatric approach. Expert Rev Neurother, 6:65-72.
17. Burns DJ, Mark MH, Playford ED, et al. 1992. Parkinson's disease in twins studied with 18F-dopa and positron emission tomography. Neurology, 42:1894-900.
18. Burns DJ. 2002. Beyond the iron mask:towards better recognition and treatment of depression associated with Parkinson's disease. Mov Disord, 17:445-54.
19. Calne DB, Langston JW, Martin WR, et al. 1985. Positron emission tomography after MPTP:observations relating to the cause of Parkinson's disease. Nature, 317:246-8.
20. Caronti B, Tanda G, Calderaro C, et al. 1999. Reduced dopamine in peripheral blood lymphocytes in Parkinson's disease. Neuroreport, 10:2907-10.
21. Caronti B, Antonini G, Calderaro C, et al. 2001. Dopamine transporter immunoreactivity in peripheral blood lymphocytes in Parkinson's disease. J Neural Transm, 108:803-7.
22. Chaudhuri KR. 2001. Autonomic dysfunction in movement disorders. Curr Opin Neurol, 14:505-11.
23. Chaudhuri KR. 2003. Noctural symptom complex in PD and its management. Neurology, 61 (Suppl 3):S17-S23.
24. 11C-WAY 10635. Mov Disord, 15:213.
25. Doty RL, Deems DA, Stellar S. 1988. Olfactory dysfunction in parkinsonism:a general deficit unrelated to neurological signs, disease stage, or disease duration. Neurology, 39:1237-44.
26. Doty RL, Stern MB, Pfeiffer C, et al. 1992. Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry, 55:138-42.
27. Doty RL, Golbe LI, McKeown DA, et al. 1993. Olfactory testing differentiates between progressive supranuclear palsy and idiopathic Parkinson's disease. Neurology, 43:962-5.
28. Eisensehr I, Linke R, Noatchar S, et al. 2000. Reduced striatal dopamine transporter in idiopathic rapid eye movement sleep behavior disorder:comparison with Parkinson's disease and controls. Brain, 123:1155-60.
29. Eckert T, Eidelberg D. 2005. Neuroimaging and therapeutics in movement disorders. NeuroRx, 2:361-71.
30. Gagnon JF, Bedard MA, Fantini ML, et al. 2002. REM sleep behavior disorder and REM sleep without atonia in Parkinson's disease. Neurology, 59:585-9.
31. Goldstein DS, Holmes C, Li ST, et al. 2000. Cardiac sympathetic denervation in Parkinson's disease. Ann Intern Med, 133:338-47.
32. Gotz ME, Gerstner A, Harth R, et al. 2000. Altered redox state of platelet coenzyme Q10 in Parkinson's disease. J Neural Transm, 107:41-8.
33. Hawkes CH, Shephard BC, Daniel SE. 1997. Olfactory dysfunction in Parkinson's disease. J Neurol Neurosurg Psychiatry, 62:436-46.
34. Hawkes CH. 2006. Olfaction in neurodegenerative disorders. Acta Otorhinolaryngol, 63:133-51.
35. Holthoff VA, Vieregge P, Kessler J, et al. 1994. Discordant twins with Parkinson's disease:positron emission tomography and early signs of impaired cognitive circuits. Ann Neurol, 36:176-82.
36. Hoyt BD. 2005. Sleep in patients with neurologic and psychiatric disorders. Prim Care, 32:535-48.
37. Hughes AJ, Daniel SE, Kilford L, et al. 1992. Accuracy of clinical diagnosis of idiopathic Parkinson's disease:a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry, 55:181-4.
38. Idiaquez J, Sandoval E, Seguel A. 2002. Association between neuropsychiatric and autonomic dysftmction in Alzheimer's disease. Clin Auton Res, 12:43-6.
39. Ilic TV, Jovanovic M, Jovicic A, et al. 1999. Oxidative stress indicators are elevated in de novo Parkinson's disease patients. Funct Neurol, 14:141-147.
40. Jenner P. 2003. Oxidative stress in Parkinson's disease. Ann Neurol, 53 (Suppl 3):S26-S36.
41. Kikuchi A, Takeda A, Onodera H, et al. 2002. Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy. Neurobiol Dis, 9:244-248.
42. Klockgether T. 2004. Parkinson's disease:clinical aspects. Cell Tissue Res, 318:115-20.
43. Lauterbach EC, Freeman A, Vogel RL. 2004. Differential DSM-III psychiatric disorder prevalence proffles in dystonia and Parkinson's disease. J Neuropsychiatry Clin Neurosci, 16:29-36.
44. Lahinen A, Ruottinen H, Rinne OJ, et al. 2000. Risk for Parkinson's disease: twin studies for the detection of asymptomatic subjects using [18F]6-fluorodopa PET. J Neurol, 247 (Suppl 2):II110-II113.
45. Magerkurth C, Schnitzer R, Braune S. 2005. Symptoms of autonomic failure in Parkinson's disease:prevatence and impact on daily life. Clin Auton Res, 15:76-82.
46. 123I]-beta-CIT-SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology, 57:2089-94.
47. Markopoulou K, Larsen KW, Wszolek EK, et al. 1997. Olfactory dysfunction in familial parkinsonism. Neurology, 49:1262-7.
48. Micieli G, Tosi P, Marcheselli S, et al. 2003. Autonomic dysfunction in Parkinson's disease. Neurol Sci, 24 (Suppl 1):S32-S34.
49. Muller A, Reichmann H, Livermore A, et al. 2002. Olfactory function in idiopathic Parkinson's disease (IPD):results from cross-sectional studies in IPD patients and long-term follow-up of de novo-IPD patients. J Neural Transm, 109:805-11.
50. Nagai Y, Ueno S, Sacki Y, et al. 1996. Decrease of the D3 dopamine receptor mRNA expression in lymphocytes from patients with Parkinson's disease. Neurology, 46:791-5.
51. Niehaus L, Savyer N, Weber U, et al. 2004. Brain parenchyma sonography in patients with essential tremor and Parkinson's disease. Cerebrovasc Dis, 17(Suppl 4):3.
52. Nilsson FM, Kessig LV, Bolwig TG. 2001. Increased risk of developing Parkinson's disease for patients with major affective disorders. Acta Psychiatr Scand, 104:380-6.
53. Olson EJ, Boeve BF, Silber MH. 2000. Rapid eye movement sleep behavior disorder:demographic, clinical and laboratory findings in 93 cases. Brain, 123:388-93.
54. Parker WD Jr, Boyson SJ, Parks JK. 1989. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol, 26:719-23.
55. Parkinson Study Group. 2000. Pramipexole versus levodopa as initial treatment for Parkinson disease:a randomized controlled trial. JAMA, 284:1931-8.
56. Piccini P, Morrish PK, Turjanski N, et al. 1997. Dopaminergic function in familial Parkinson's disease:a clinical and 18F-dopa positron emission tomography study. Ann Neurol, 41:222-9.
57. Ponsen MM, Stoffers D, Booij J, et al. 2004. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol, 56:173-81.
58. Rascol O, Goetz C, Koller W, et al. 2002. Treatment interventions for Parkinson's disease:an evidence based assessment. Lancet, 359:1589-98.
59. Remy P, Doder M, Lees A, et al. 2005. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain, 128:1314-22.
60. Saper C, Chou TC, Scammell TE. 2001. The sleep switch:hypothalamic control of sleep and wakefulness. Trends Neurosci, 24:726-31.
61. Schenk CH, Bundlie SR, Mahowald MW. 1996. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder. Neurology, 46:388-93.
62. Schurmann AG, Van Den Akker H, Ensinck KTJL, et al. 2002. Increased risk of Parkinson's disease after depression:a retrospective cohort study. Neurology, 58:1501-4.
63. 123I]IPT and single photon emission computed tomography in patients with early Parkinson's disease: implications for a preclinical diagnosis. Arch Neurol, 57:205-8.
64. Shapira AH, Cooper JM, Dexter D, et al. 1990. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 54:823-7.
65. Shiba M, Bower JH, Maraganore DM, et al. 2000. Anxiety disorders and depressive disorders preceding Parkinson's disease:a case-control study. Mov Disord, 15:669-77.
66. Singleton A, Gwinn-Hardy K. Sharabi Y. 2004. Association between cardiac denervation and parkinsonism caused by alpha-synuclein gene triplication. Brain, 127:768-72.
67. Sommer U, Hummel T, Cormann K, et al. 2004. Detection of presymptomatic Parkinson's disease: combinating smell tests, transcranial sonography, and SPECT. Mov Disord, 19:1196-202.
68. Stiasny-Kolster K, Doerr Y, Moller JC, et al. 2005. Combination of idiopathic REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain, 128:126-37.
69. Tissingh G, Berendse HW, Bergmans P, et al. 2001. Loss of olfaction in de novo and treated Parkinson's disease:possible implications for early diagnosis. Mov Disord, 16:41-6.
70. Tracik F, Ebersbach G. 2001. Sudden daytime sleep onset in Parkinson's disease:polysomnographic recordings. Mov Disord, 16:500-6.
71. Walter U, Wittstock M, Benecke R, et al. 2002. Substantia nigra hecogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinson's disease. J Neural Transm, 109:191-6.
72. Walter U, Niehaus L, Probst T, et al. 2003. Brain parenchyma sonography discriminates Parkinson's disease and atypical parkinsonian syndromes. Neurology, 60:74-7.
73. Walter U, Klein C, Hilker R, et al. 2004. Deep brain parenchyma sonography detects preclinical parkinsonism. Mov Disord, 19:1445-9.
74. Weisskopf MG, Chen H, Schwarzchild MA, et al. 2003, Prospective study of phobic anxiety and risk of Parkinson's disease. Mov Disord, 18:646-51.
75. Wenning GK, Shepard B, Hawkes C, et al. 1995. Olfactory function in atypical parkinsonian syndromes. Acta Neurol Scand, 91:247-50.
76. Whone AL, Watts RL, Stoessl AJ, et al. 2003. Slower progression of Parkinson's disease with ropinirole versus levodopa:the REAL-PET study. Ann Neurol, 54:93-101.
77. Wolters EC, Francot C, Bergmans P, et al. 2000. Preclinical (premotor) Parkinson's disease. J Neurol, 247 (suppl. 2):11103-9.
78. Zedde M, Manca A, Baude G, et al. 2005. Brain parenchyma sonography (BPS) of substantia nigra (SN) in Parkinson's disease. Parkinsonism & Rel Dis, 11(Suppl 2):222.